2007-2018年美国针对阿片类 epidemic 的州级政策干预措施的系统评价
这项横断面研究利用2007-2018年50个州的药物过量死亡数据和2300万商业保险患者的索赔数据,采用双重差分分析和随机效应荟萃分析,评估6项州级毒品政策与处方阿片滥用、阿片使用障碍和过量诊断、药物辅助治疗(MAT)处方及药物过量死亡的关系。强制性PDMP与阿片处方比例、重叠阿片索赔、每日吗啡毫克当量大于90及寻药行为比例下降相关,并使MAT比例增加;强制性PDMP还与天然阿片和美沙酮过量死亡减少相关。PDMP访问政策结果类似,但与合成阿片和可卡因过量死亡增加相关。除处方限制法与合成阿片死亡负相关外,其他政策与过量死亡增加相关,尤其是非处方阿片(合成阿片和海洛因)。作者认为现有州政策虽与处方阿片滥用减少相关,但可能促使阿片使用障碍者转向非法药物市场,可能增加过量死亡。
要点
- 强制性PDMP与阿片处方患者比例下降0.729%(95%CI -1.011%至-0.447%)、重叠阿片索赔下降0.027%(95%CI -0.038%至-0.017%)相关。
- 强制性PDMP与每日吗啡毫克当量大于90的比例下降0.095%(95%CI -0.150%至-0.041%)、寻药行为比例下降0.002%(95%CI -0.003%至-0.001%)相关。
- 强制性PDMP、疼痛诊所法和处方限制法均与MAT处方比例增加相关,分别为0.015%(95%CI 0.002%-0.028%)、0.013%(95%CI 0.005%-0.021%)和0.034%(95%CI 0.020%-0.049%)。
- 强制性PDMP与天然阿片过量死亡减少518.5例/3亿人(95%CI -728.5至-308.5)和美沙酮过量死亡减少122.7例/3亿人(95%CI -207.5至-37.8)相关。
- 纳洛酮获取法与合成阿片过量死亡增加1338.2例/3亿人(95%CI 662.5-2014.0)相关;处方限制法与合成阿片过量死亡减少723.9例/3亿人(95%CI -1419.7至-28.1)相关。
适用人群与场景
- 美国50个州的药物过量死亡数据,以及2007-2018年2300万商业保险患者(女性12 582 378例[55.1%];平均[SD]年龄45.9[19.9]岁)的索赔数据。
研究设计与关键结果
- 研究类型:横断面研究,使用2007-2018年美国50个州的国家生命统计系统药物过量死亡数据和2300万商业保险患者索赔数据,采用面板匹配的双重差分分析评估6项州级政策实施前后的结局,并用随机效应荟萃分析模型总结各政策与结局对的随时间关联;数据分析于2020年7月12日进行。
- 强制性PDMP与阿片处方患者比例下降0.729%(95%CI -1.011%至-0.447%)、重叠阿片索赔下降0.027%(95%CI -0.038%至-0.017%)、每日吗啡毫克当量大于90的比例下降0.095%(95%CI -0.150%至-0.041%)、寻药行为比例下降0.002%(95%CI -0.003%至-0.001%)相关。
- MAT处方患者比例在强制性PDMP实施后增加0.015%(95%CI 0.002%至0.028%),疼痛诊所法后增加0.013%(95%CI 0.005%-0.021%),处方限制法后增加0.034%(95%CI 0.020%至0.049%)。
- 强制性PDMP与天然阿片过量死亡减少518.5例/3亿人(95%CI -728.5至-308.5)和美沙酮过量死亡减少122.7例/3亿人(95%CI -207.5至-37.8)相关。
- PDMP访问政策显示类似结果,但也与合成阿片过量死亡增加380.3例/3亿人(95%CI 149.6-610.8)和可卡因过量死亡增加103.7例/3亿人(95%CI 28.0-179.5)相关。
- 除处方限制法与合成阿片死亡负相关(-723.9例/3亿人,95%CI -1419.7至-28.1)外,其他政策与过量死亡增加相关,尤其是合成阿片和海洛因等非处方阿片;纳洛酮获取法与合成阿片死亡增加1338.2例/3亿人(95%CI 662.5至2014.0)正相关。
证据类型、等级与局限
- 证据类型:横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,现有州政策虽与处方阿片滥用减少相关,但可能产生非预期后果,促使阿片使用障碍者转向非法药物市场,可能增加过量死亡。
- 作者认为,这一发现提示没有简单的政策解决方案来逆转美国的阿片依赖和死亡 epidemic。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: In response to the increase in opioid overdose deaths in the United States, many states recently have implemented supply-controlling and harm-reduction policy measures. To date, an updated policy evaluation that considers the full policy landscape has not been conducted.
OBJECTIVE: To evaluate 6 US state-level drug policies to ascertain whether they are associated with a reduction in indicators of prescription opioid abuse, the prevalence of opioid use disorder and overdose, the prescription of medication-assisted treatment (MAT), and drug overdose deaths.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used drug overdose mortality data from 50 states obtained from the National Vital Statistics System and claims data from 23 million commercially insured patients in the US between 2007 and 2018. Difference-in-differences analysis using panel matching was conducted to evaluate the prevalence of indicators of prescription opioid abuse, opioid use disorder and overdose diagnosis, the prescription of MAT, and drug overdose deaths before and after implementation of 6 state-level policies targeting the opioid epidemic. A random-effects meta-analysis model was used to summarize associations over time for each policy and outcome pair. The data analysis was conducted July 12, 2020.
EXPOSURES: State-level drug policy changes to address the increase of opioid-related overdose deaths included prescription drug monitoring program (PDMP) access, mandatory PDMPs, pain clinic laws, prescription limit laws, naloxone access laws, and Good Samaritan laws.
MAIN OUTCOMES AND MEASURES: The outcomes of interests were quarterly state-level mortality from drug overdoses, known indicators for prescription opioid abuse and doctor shopping, MAT, and prevalence of drug overdose and opioid use disorder.
RESULTS: This cross-sectional study of drug overdose mortality data and insurance claims data from 23 million commercially insured patients (12 582 378 female patients [55.1%]; mean [SD] age, 45.9 [19.9] years) in the US between 2007 and 2018 found that mandatory PDMPs were associated with decreases in the proportion of patients taking opioids (-0.729%; 95% CI, -1.011% to -0.447%), with overlapping opioid claims (-0.027%; 95% CI, -0.038% to -0.017%), with daily morphine milligram equivalent greater than 90 (-0.095%; 95% CI, -0.150% to -0.041%), and who engaged in drug seeking (-0.002%; 95% CI, -0.003% to -0.001%). The proportion of patients receiving MAT increased after the enactment of mandatory PDMPs (0.015%; 95% CI, 0.002% to 0.028%), pain clinic laws (0.013%, 95% CI, 0.005%-0.021%), and prescription limit laws (0.034%, 95% CI, 0.020% to 0.049%). Mandatory PDMPs were associated with a decrease in the number of overdose deaths due to natural opioids (-518.5 [95% CI, -728.5 to -308.5] per 300 million people) and methadone (-122.7 [95% CI, -207.5 to -37.8] per 300 million people). Prescription drug monitoring program access policies showed similar results, although these policies were also associated with increases in overdose deaths due to synthetic opioids (380.3 [95% CI, 149.6-610.8] per 300 million people) and cocaine (103.7 [95% CI, 28.0-179.5] per 300 million people). Except for the negative association between prescription limit laws and synthetic opioid deaths (-723.9 [95% CI, -1419.7 to -28.1] per 300 million people), other policies were associated with increasing overdose deaths, especially those attributed to non-prescription opioids such as synthetic opioids and heroin. This includes a positive association between naloxone access laws and the number of deaths attributed to synthetic opioids (1338.2 [95% CI, 662.5 to 2014.0] per 300 million people).
CONCLUSIONS AND RELEVANCE: Although this study found that existing state policies were associated with reduced misuse of prescription opioids, they may have the unintended consequence of motivating those with opioid use disorders to access the illicit drug market, potentially increasing overdose mortality. This finding suggests that there is no easy policy solution to reverse the epidemic of opioid dependence and mortality in the US.
参考来源
- Lee B, Zhao W, Yang KC, et al. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018. JAMA Netw Open. 2021. PMID: 33576816. doi:10.1001/jamanetworkopen.2020.36687
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。